^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    GBP4 (Guanylate Binding Protein 4)

    i
    Other names: GBP4, Guanylate Binding Protein 4, Mpa2, Guanine Nucleotide-Binding Protein 4, Guanylate-Binding Protein 4, GTP-Binding Protein 4, GBP-4
    Associations

    News

    Trials
    5ms
    Integrated transcriptome and single-cell RNA sequencing analysis revealed the prognostic significance of GBP4 in pancreatic adenocarcinoma. (PubMed, Transl Oncol)
    This study identifies GBP4-related prognostic genes and demonstrates the role of GBP4 in pancreatic cancer progression, providing new perspectives for prognostic prediction and therapeutic targeting.
    Journal
    |
    CD8 (cluster of differentiation 8) • BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • GBP4 (Guanylate Binding Protein 4) • KRT6A (Keratin 6A) • MMP7 (Matrix metallopeptidase 7)
    7ms
    Macrophage-Related GBP4 as a Novel Biomarker for Crohn's Disease: Insights from WGCNA, Mendelian Randomization, and Immunohistochemical Validation. (PubMed, Curr Top Med Chem)
    Our findings highlight GBP4 as a novel potential biomarker and therapeutic target in CD, providing insights into the immune-mediated mechanisms underlying the disease. These results contribute to a better understanding of CD pathogenesis and may lead to new therapeutic strategies.
    Journal
    |
    GBP4 (Guanylate Binding Protein 4)
    7ms
    A randomized, open-label, multicenter clinical study comparing the combination of epalorlimovalizumab and bevacizumab with TAS-102 versus bevacizumab combined with TAS-102 in the second-line treatment of advanced colorectal cancer (ChiCTR2500106797)
    P4, N=84, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GBP5 (Guanylate Binding Protein 5) • STAT1 (Signal Transducer And Activator Of Transcription 1) • APOE (Apolipoprotein E) • GBP1 (Guanylate Binding Protein 1) • TAP1 (Transporter 1) • GBP4 (Guanylate Binding Protein 4) • MX1 (MX Dynamin Like GTPase 1) • SDC2 (Syndecan 2)
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    9ms
    Regulatory effects of lncRNA PVT1 on transcriptome in human breast cancer MDA-MB-231 cell line determined by in silico analyses. (PubMed, Chromosoma)
    RT-qPCR validated the anticipated levels of PVT1, miR-145-5p, and SERPINE1 in MDA-MB-231 cancer compared to MCF-10 A noncancerous cells. Taken together, the results of this work shed light on the several possible oncogenic mechanisms of PVT1, including its closely related genes and signaling pathways.
    Preclinical • Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • SERPINE1 (Serpin Family E Member 1) • MIR17 (MicroRNA 17) • PRLR (Prolactin Receptor 2) • PVT1 (Pvt1 Oncogene) • DHRS2 (Dehydrogenase/Reductase 2) • GBP4 (Guanylate Binding Protein 4) • MIR145 (MicroRNA 145) • MIR20A (MicroRNA 20a)
    11ms
    Transcriptional and microbial profile of gastric cancer patients infected with Epstein-Barr virus. (PubMed, Front Oncol)
    These findings suggest a complex interaction between the host (EBV+ GC) and the microbiota, possibly influencing cancer progression, and offering potential therapeutic targets such as microbiota modulation or gene regulation. Comparing with EBV- samples further highlights the specific impact of EBV and the microbiota on gastric cancer pathogenesis.
    Journal
    |
    ICAM1 (Intercellular adhesion molecule 1) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • GBP5 (Guanylate Binding Protein 5) • IL32 (Interleukin 32) • TNFSF10 (TNF Superfamily Member 10) • GBP4 (Guanylate Binding Protein 4)
    over1year
    DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. (PubMed, Cancer Immunol Immunother)
    Lastly, in vitro T cell killing assays using primary organoids suggested that the PDAC samples with high level of GBP4 expression displayed significantly higher sensitivity to anti-PD-1 treatment. Taken together, our studies revealed the expression patterns and epigenetic regulatory mechanisms of GBP4 in pancreatic cancer and clarified the effects of GBP4 on T cell exhaustion and antitumor immunology.
    Journal • PD(L)-1 Biomarker • IO biomarker • Epigenetic controller
    |
    CD8 (cluster of differentiation 8) • GBP4 (Guanylate Binding Protein 4)
    over1year
    Identification of prognostic RNA editing profiles for clear cell renal carcinoma. (PubMed, Front Med (Lausanne))
    RNA editing site-based prognostic models are valuable in differentiating between high and low-risk populations. The seven identified RNA editing sites may be utilized as potential biomarkers for ccRCC.
    Journal
    |
    GBP4 (Guanylate Binding Protein 4)
    almost2years
    Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers. (PubMed, Cancer Res)
    Further integrative and functional analyses identified GBP4 demethylation, which is highly prevalent in the S2 and S3 groups, as an epigenetic oncogenic factor that regulates iCCA proliferation, migration, and invasion. Together, this study identifies prognostic methylome alterations and epigenetic drivers in iCCA.
    Journal • Tumor mutational burden • Epigenetic controller
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • BAP1 (BRCA1 Associated Protein 1) • GBP4 (Guanylate Binding Protein 4)
    |
    TMB-H • FGFR2 mutation • FGFR2 fusion • BAP1 mutation
    2years
    Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. (PubMed, J Cancer Res Clin Oncol)
    GBP4 expression profiles offer a promising avenue for identifying highly immunogenic tumors across a wide spectrum of cancers. GBP4 holds potential as a robust pan-cancer biomarker for assessing the immunological characteristics of tumors, with particular relevance to its ability to predict therapeutic responses, notably in the context of anti-EGFR therapy and immunotherapy.
    Journal • IO biomarker
    |
    GBP4 (Guanylate Binding Protein 4)
    2years
    Identification of AP002498.1 and LINC01871 as prognostic biomarkers and therapeutic targets for distant metastasis of colorectal adenocarcinoma. (PubMed, Cancer Med)
    The DElncRNA AP002498.1 and the LINC01871/miR-4644 and miR-185-5p/GNLY axes were identified as being closely associated with distant metastasis and could represent independent prognostic biomarkers or therapeutic targets in colorectal adenocarcinoma.
    Journal • IO biomarker
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • NOS2 (Nitric Oxide Synthase 2) • miR-185 (MicroRNA 185) • GBP4 (Guanylate Binding Protein 4) • LINC01871 (Long Intergenic Non-Protein Coding RNA 1871) • SERPINA1 (Serpin Family A Member 1) • MIR4644 (MicroRNA 4644)
    over2years
    Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature. (PubMed, Sci Rep)
    Based on the finding, we can claim that there is a clear link between chemokines and TME in SKCM. The risk score may perform as a trustworthy prediction model, giving therapeutic benefits for both chemotherapy and immunotherapy, as well as being beneficial for clinical decision making in SKCM patients.
    Journal • Gene Signature • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2RA (Interleukin 2 receptor, alpha) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • IRF1 (Interferon Regulatory Factor 1) • CCL8 (C-C Motif Chemokine Ligand 8) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • GBP4 (Guanylate Binding Protein 4)
    |
    IRF1 expression
    over2years
    Transcriptome analysis reveals tumor antigen and immune subtypes of melanoma. (PubMed, Oncol Res)
    After IDO1 knockdown, the activity, invasion, migration and healing ability of A375 cell lines were significantly decreased. Our study could provide a reference for the development of vaccines for melanoma patients.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD79A (CD79a Molecule) • GZMB (Granzyme B) • GBP4 (Guanylate Binding Protein 4)